The Risk of Early Recurrent MI: What is the Role of Cholesterol Efflux and ApoA-I? - report from ACC2023

Prosessor Eliot A. Brinton on the risk and incidence of recurrent CV events post-AMI, and the role of cholesterol efflux and ApoA-I in plaque stabilization. There is a large clinical trial ongoing, that have results in the next 1-2 years. Let's keep tuned to this study and see what we see in the near future. Video: https://medicaldigest.org/scientific-contents/interview:risk-early-recurrent-mi-what-role-cholesterol-efflux-and-apoa-i